Vironexis Biotherapeutics Revenue and Competitors
Employee Data
- Vironexis Biotherapeutics has 8 Employees.
- Vironexis Biotherapeutics grew their employee count by 33% last year.
Vironexis Biotherapeutics's People
| Name | Title | Email/Phone |
|---|
Vironexis Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is Vironexis Biotherapeutics?
Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.
keywords:N/A
N/A
Total Funding
8
Number of Employees
N/A
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 8 | -20% | N/A |
#2 | $0.6M | 8 | N/A | N/A |
#3 | $0.6M | 8 | N/A | N/A |
#4 | $0.6M | 8 | N/A | N/A |
#5 | $0.6M | 8 | N/A | N/A |